IL37 and congenital rubella syndrome: Although therapeutic drugs like Tocilizumab (IL-6 inhibitor) and Daclizumab (IL-2 inhibitor) have been shown to reduce CRS grade [31,32], new studies have shown, specifically that anti-inflammatory cytokines like IL-37 and IL-38 have inhibitive effects on IL-1, which in the recent SARS CoV-2 (COVID-19) pandemic outbreak has played a part in our understanding of cytokine release and cytokine-related inflammation [33].